Empagliflozin Monotherapy for 12 Weeks Improves Glycemic Control in Japanese Patients With Type 2 Diabetes (T2DM)

被引：0
|
作者：
Kadowaki, Takashi
Haneda, Masakazu
Inagaki, Nobuya
Taniguchi, Atsushi
Sakamoto, Masashi
Koiwai, Kazuki
Rattunde, Henning
Woerle, Hans J.
Broedl, Uli C.
机构：
来源：
DIABETES | 2013年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1144-P
引用
收藏
页码：A297 / A298
页数：2
相关论文
共 50 条
  • [41] DELAYED TREATMENT MODIFICATIONS FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) WITH VERY POOR GLYCEMIC CONTROL
    Schwab, P.
    Saundankar, V
    Bouchard, J. R.
    Moretz, C.
    Baltz, J.
    VALUE IN HEALTH, 2014, 17 (03) : A264 - A264
  • [42] Safety and Tolerability of Combinations of Empagliflozin/Linagliptin (EMPA/LINA) for 52 Weeks in Subjects with Type 2 Diabetes (T2DM)
    Patel, Sanjay
    Defronzo, Ralph A.
    Lewin, Andrew
    Liu, Dacheng
    Kaste, Renee
    Kohler, Sven
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2015, 64 : A326 - A327
  • [43] Adherence to Treatment Guidelines in Type 2 Diabetes (T2DM) Patients Treated with Metformin (MET) Monotherapy with Suboptimal Glycemic Control in Israeli Managed Care
    Goldshtein, Inbal
    Tunceli, Kaan
    Radican, Larry
    Katzeff, Harvey
    Yu, Shengsheng
    Voss, Bernd
    Sharon, Ofer
    Gadir, Noga
    Brodovicz, Kimberly
    Shalev, Varda
    Chodik, Gabriel
    Karasik, Avraham
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 111 - 111
  • [44] Adherence to Treatment Guidelines in Type 2 Diabetes (T2DM) Patients Treated with Metformin (MET) Monotherapy with Suboptimal Glycemic Control in Israeli Managed Care
    Tunceli, Kaan
    Goldstein, Inbal
    Radican, Larry
    Katzeff, Harvey
    Yu, Shengsheng
    Voss, Bernd
    Sharon, Ofer
    Gadir, Noga
    Brodovicz, Kimberly
    Shalev, Varda
    Chodik, Gabriel
    Karasik, Avraham
    DIABETES, 2014, 63 : A304 - A304
  • [45] Rosiglitazone improves exercise capacity in type 2 diabetes (T2DM)
    Regensteiner, J
    Bauer, TA
    Reusch, JEB
    DIABETES, 2004, 53 : A8 - A9
  • [46] Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes
    Tajima, Naoko
    Kadowaki, Takashi
    Okamoto, Taro
    Sato, Asako
    Okuyama, Kotoba
    Minamide, Toshiomi
    Ferreira, Juan Camilo Arjona
    JOURNAL OF DIABETES INVESTIGATION, 2013, 4 (06) : 595 - 604
  • [47] Efficacy and Safety of Canagliflozin (CANA) Monotherapy in Subjects With Type 2 Diabetes Mellitus (T2DM) Over 52 Weeks
    Stenloef, Kaj
    Cefalu, William T.
    Kim, Kyoung-Ah
    Jodar, Esteban
    Alba, Maria
    Edwards, Robert
    Tong, Cindy
    Canovatchel, William
    Meininger, Gary
    DIABETES, 2013, 62 : A303 - A303
  • [48] Improvements in Glycemic Control are Associated With a Decline in the Severity of Depressive Symptoms in Patients With Type 2 Diabetes Mellitus (T2DM)
    Dzida, Grzegorz J.
    Karnieli, Eddy
    Svendsen, Anne Louise
    Hermanns, Norbert
    DIABETES, 2013, 62 : A212 - A212
  • [49] The DPP-4 inhibitor, LAF237, improves glycemic control in patients with type 2 diabetes (T2DM) inadequately treated with metformin
    Ahren, B
    Gomis, R
    Mills, D
    Schweizer, A
    DIABETES, 2004, 53 : A83 - A83
  • [50] Retrospective study of type 2 diabetes mellitus (T2DM) patients not optimally controlled by metformin monotherapy
    He, J.
    Neslusan, C.
    VALUE IN HEALTH, 2008, 11 (03) : A18 - A18
12345